{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:34:02Z","timestamp":1791952442635,"version":"4.3.4"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Melioidosis is an opportunistic infection caused by Burkholderia pseudomallei. Prolonged IV antibiotic therapy is required to cure the disease. Current guidelines recommend daily ceftazidime for people receiving chronic intermittent haemodialysis (CIHD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We reviewed all cases of culture-confirmed B. pseudomallei infection from 2016 to 2025. In patients receiving CIHD, we recorded their weekly CIHD schedule, their ceftazidime dosing regimen, the ceftazidime MIC for their initial B. pseudomallei isolate and all pre-dialysis ceftazidime concentrations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were 449 cases of melioidosis; 26 (5.8%) occurred in people already receiving\u2014or who were commenced on\u2014CIHD during their hospital admission. Of these, 24 (92%) survived to the completion of their intensive IV phase of antibiotic therapy. There were nine who had ceftazidime pre-dialysis concentrations measured. Of these, eight were commenced on ceftazidime 2\u2005g daily, but five had their dosing regimen changed; this was a daily dose reduction in three and a change to thrice-weekly dosing regimen of 2\u2005g\/2\u2005g\/3\u2005g post-haemodialysis in two. One patient was administered thrice-weekly dosing post-haemodialysis for the duration of their intensive phase. No cases had evidence of neurotoxicity, all received oral eradication therapy, and all had clinical cure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients receiving thrice-weekly CIHD, post-haemodialysis ceftazidime administered 2\u2005g\/2\u2005g\/3\u2005g achieved adequate serum pre-dialysis concentrations, can achieve good clinical outcomes and may be a potential treatment approach for people with melioidosis. The availability of therapeutic drug monitoring and clinical breakpoints suggest a more individualized approach is possible in people with melioidosis receiving CIHD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf383","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T12:06:50Z","timestamp":1758888410000},"page":"3386-3390","source":"Crossref","is-referenced-by-count":5,"title":["Thrice-weekly post-haemodialysis ceftazidime can achieve adequate pre-dialysis concentrations and clinical cure in patients with melioidosis"],"prefix":"10.1093","volume":"80","author":[{"given":"Simon","family":"Smith","sequence":"first","affiliation":[{"name":"Department of Medicine, Cairns Hospital , Cairns, Queensland ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher W","family":"Reilly","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cairns Hospital , Cairns, Queensland ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Stewart","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cairns Hospital , Cairns, Queensland ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ragh","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cairns Hospital , Cairns, Queensland ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa J","family":"Muller","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cairns Hospital , Cairns, Queensland ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Ismail","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cairns Hospital , Cairns, Queensland ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1423-3839","authenticated-orcid":false,"given":"Josh","family":"Hanson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cairns Hospital , Cairns, Queensland ,","place":["Australia"]},{"name":"Kirby Institute, University of New South Wales , Sydney, New South Wales ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"2025120206223931200_dkaf383-B1","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/S1473-3099(21)00022-0","article-title":"The Darwin prospective melioidosis study: a 30-year prospective, observational investigation","volume":"21","author":"Currie","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2025120206223931200_dkaf383-B2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/tropicalmed3010027","article-title":"Melioidosis: an Australian perspective","volume":"3","author":"Smith","year":"2018","journal-title":"Trop Med Infect Dis"},{"key":"2025120206223931200_dkaf383-B3","doi-asserted-by":"publisher","first-page":"e0008659","DOI":"10.1371\/journal.pntd.0008659","article-title":"2020 Review and revision of the 2015 Darwin melioidosis treatment guideline; paradigm drift not shift","volume":"14","author":"Sullivan","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"2025120206223931200_dkaf383-B4","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/j.1365-3156.2004.01244.x","article-title":"Out of hospital treatment of patients with melioidosis using ceftazidime in 24 h elastomeric infusors, via peripherally inserted central catheters","volume":"9","author":"Huffam","year":"2004","journal-title":"Trop Med Int Health"},{"key":"2025120206223931200_dkaf383-B5","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1128\/AAC.39.8.1797","article-title":"Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model","volume":"39","author":"Cappelletty","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206223931200_dkaf383-B6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ijantimicag.2014.04.012","article-title":"Current antimicrobial susceptibility of first-episode melioidosis Burkholderia pseudomallei isolates from the Northern Territory, Australia","volume":"44","author":"Crowe","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2025120206223931200_dkaf383-B7","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/ki.2014.228","article-title":"Melioidosis and end-stage renal disease in tropical Northern Australia","volume":"86","author":"Chalmers","year":"2014","journal-title":"Kidney Int"},{"key":"2025120206223931200_dkaf383-B8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1128\/AAC.25.2.201","article-title":"Pharmacokinetics of ceftazidime in patients with renal insufficiency","volume":"25","author":"Welage","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206223931200_dkaf383-B9","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/jac\/dks468","article-title":"Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia","volume":"68","author":"Muller","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2025120206223931200_dkaf383-B10","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/j.1440-1681.2012.05715.x","article-title":"\u03b2-Lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review","volume":"39","author":"Sinnollareddy","year":"2012","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2025120206223931200_dkaf383-B11","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s40265-021-01469-2","article-title":"Post-dialysis parenteral antimicrobial therapy in patients receiving intermittent high-flux hemodialysis","volume":"81","author":"Cimino","year":"2021","journal-title":"Drugs"},{"key":"2025120206223931200_dkaf383-B12","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1093\/jac\/dkz096","article-title":"Successful treatment of Pseudomonas aeruginosa infective endocarditis via haemodialysis outpatient parenteral antimicrobial therapy: case report","volume":"74","author":"Maxwell-Scott","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2025120206223931200_dkaf383-B13","doi-asserted-by":"publisher","first-page":"e0005411","DOI":"10.1371\/journal.pntd.0005411","article-title":"The epidemiology and clinical features of melioidosis in Far North Queensland: implications for patient management","volume":"11","author":"Stewart","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"2025120206223931200_dkaf383-B14","doi-asserted-by":"publisher","first-page":"e0003586","DOI":"10.1371\/journal.pntd.0003586","article-title":"Intravenous therapy duration and outcomes in melioidosis: a new treatment paradigm","volume":"9","author":"Pitman","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"2025120206223931200_dkaf383-B15","volume-title":"Department of Health Engagement Suite: Framework","author":"Western Australian Department of Health","year":"2017"},{"key":"2025120206223931200_dkaf383-B16","doi-asserted-by":"publisher","first-page":"151467","DOI":"10.1016\/j.semnephrol.2023.151467","article-title":"Strategies to prevent infections in dialysis patients","volume":"43","author":"Ponce","year":"2023","journal-title":"Semin Nephrol"},{"key":"2025120206223931200_dkaf383-B17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jhin.2024.07.003","article-title":"Comparison of complication rates between midline catheters and peripherally inserted central catheters: a systematic review and meta-analysis of randomized controlled trials","volume":"151","author":"Lai","year":"2024","journal-title":"J Hosp Infect"},{"key":"2025120206223931200_dkaf383-B18","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.3201\/eid2712.211302","article-title":"Increased incidence of melioidosis in Far North Queensland, Queensland, Australia, 1998\u20132019","volume":"27","author":"Smith","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"2025120206223931200_dkaf383-B19","doi-asserted-by":"publisher","first-page":"107559","DOI":"10.1016\/j.actatropica.2025.107559","article-title":"Melioidosis in people living with diabetes; clinical presentation, clinical course and implications for patient management","volume":"263","author":"Prideaux","year":"2025","journal-title":"Acta Trop"},{"key":"2025120206223931200_dkaf383-B20","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s15010-023-02167-9","article-title":"Ceftazidime-related neurotoxicity in a patient with renal impairment: a case report and literature review","volume":"52","author":"Vanneste","year":"2024","journal-title":"Infect"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/12\/3386\/64647437\/dkaf383.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/12\/3386\/64647437\/dkaf383.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T11:22:43Z","timestamp":1764674563000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/12\/3386\/8284724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":20,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,10,13]]},"published-print":{"date-parts":[[2025,12,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf383","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,13]]}}}